Nycomed & Merck fail to convince NICE about Daxas in COPD
This article was originally published in Scrip
Executive Summary
Draft guidance from NICE is recommending that Nycomed and Merck provide evidence of how Daxas roflumilast performs in its likely clinical setting as an add-on to conventional therapies of chronic obstructive pulmonary disorder (COPD). NICE's appraisal committee says there is great uncertainty about the effect of roflumilast on reducing the rate of exacerbations as an add-on to triple or dual therapy for people with severe COPD. There was also some question of whether trials of roflumilast were conducted against appropriate comparators such as theophylline.